Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  EGFR inhibitor AZD9291
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-10 of 10 for your search:
Start Over
AZD9291 Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D5160C00003, NCT02151981
AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D5160C00007, 2014-002694-11, NCT02296125
AZD9291 First Time In Patients Ascending Dose Study
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D5160C00001, NCT01802632
Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D5160C00017, NCT02442349
AZD9291 in Combination With Ascending Doses of Novel Therapeutics
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D5160C00006, NCT02143466
Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment
Phase: Phase I
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D5160C00008, 2014-001515-39, NCT02161770
Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC
Phase: Phase I
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D5160C00014, NCT02197234
Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC
Phase: Phase I
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D5160C00013, 2014-001525-32, NCT02197247
Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D5160C00019, NCT02317016
Start Over